A novel CDS-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5
Pm. Gray et al., A novel CDS-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5, J VIROLOGY, 75(21), 2001, pp. 10065-10072
Adoptive transfer studies have shown that cytotoxic T lymphocytes (CTL) of
high avidity, capable of recognizing low levels of peptide-MHC I molecules,
are more efficient at reducing viral titers than are low-avidity CTL, thus
establishing CTL avidity as a critical parameter for the ability of a CTL
to clear virus in vivo. It has been well documented that CTL of high avidit
y are relatively CD8 independent, whereas low-avidity CTL require CD8 engag
ement in order to become activated. In this study we have analyzed the anti
viral CTL response elicited following infection with the paramyxovirus simi
an virus 5 (SV5). We have identified the immunodominant and subdominant CTL
responses and subsequently assessed the avidity of these responses by thei
r CD8 dependence. This is the first study in which the relationship between
immunodominance and CTL avidity has been investigated. The immunodominant
response was directed against an epitope present in the viral M protein, an
d subdominant responses were directed against epitopes present in the P, F,
and HN proteins. Similarly to other CTL responses we have analyzed, the im
munodominant response and the subdominant F and HN responses were comprised
of both high- and low-avidity CTL. However, the subdominant response direc
ted against the epitope present in the P protein is novel, as it is exclusi
vely high avidity. This high-avidity response is independent of both the ro
ute of infection and expression by recombinant SV5. A further understanding
of the inherent properties of P that elicit only high-avidity CTL may allo
w for the design of more efficacious vaccine vectors that preferentially el
icit high-avidity CTL in vivo.